Kursziel : 6$
Canaccord Genuity maintains a 'Buy' on Cytokinetics (NASDAQ: CYTK), PT $6.
Canaccord analyst says, "CK357 Phase 2 ALS efficacy data shows promise of real clinical benefit in ALS. We think CK357 has a strong mechanistic rationale in ALS and muscle-wasting diseases, and very promising new Phase 2 efficacy data. We think CYTK’s partner Amgen will continue to advance Phase 2 omecamtiv in heart failure trials in 2011. Our $6 price target is based on a pNPV analysis."
For more ratings news on Cytokinetics click here and for the rating history of Cytokinetics click here.
Shares of Cytokinetics closed at $2.93 yesterday, with a 52 week range of $2.03-$3.80.
|aus der Diskussion:||ALS - Biotech machts möglich?|
|Autor (Datum des Eintrages):||Karl79 (13.12.10 17:52:55)|
|Beitrag:||2 von 9 (ID:40701965)|
|Alle Angaben ohne Gewähr © wallstreet:online|